Integrated Omics Analysis of Pain: Omics Data Generation Center

疼痛的综合组学分析：组学数据生成中心

• 批准号: 10611195
• 负责人: TIMOTHY D HOWARD
• 金额: $ 50万
• 依托单位: WAKE FOREST UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-01 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10611195
• 关键词: Acute; Administrative Supplement; Biological Markers; California; Charge; Collaborations; Complement; Data; Ensure; Funding; Generations; Goals; Hybrids; Lipids; Liquid Chromatography; Mass Fragmentography; Operative Surgical Procedures; Pain; Participant; Patient Recruitments; Patients; Plasma; Resolution; Sampling; Surface; Universities; base; biomarker signature; chronic pain; clinical research site; forest; lipidomics; medical schools; metabolomics; novel; pain chronification; participant enrollment; precision medicine

SUMMARY The goal of the WF ODGC is to generate metabolomics and lipidomics data on plasma samples collected from participants of the A2CPS Consortium, and to discover novel metabolomic and/or lipidomic signatures that are associated with the conversion from acute to chronic pain. We use high resolution HILIC-MS/MS and high resolution GC-MS for the characterization of metabolites, and charged surface hybrid liquid chromatography- high resolution accurate mass MS/MS in positive and negative electrospray mode to characterize plasma lipids. The ODGC is a collaboration between the Center for Precision Medicine at the Wake Forest University School of Medicine and the West Coast Metabolomics Center at the University of California at Davis. This request for an Administrative Supplement is necessitated by the unforeseen delay in patient recruitment and enrollment at the two Clinical sites, MCC1 and MCC2, and the resulting delay in sample analysis at the ODGC. Based on the estimates from the MCCs, it is anticipated that all samples for metabolomics and lipidomics analysis (8400 samples total) will be collected by the end of August 2025, and analysis, data and sample transfer will be completed by the ODGC by the end of May, 2026. The requested supplement will ensure the successful analysis of the entire complement of samples, characterization and quantification of preselected secondary biomarkers, and integration of the resulting biomarker data with other biomarker information collected for the Consortium.

摘要 WF ODGC的目标是在从以下地点收集的血浆样本上生成代谢组学和脂质组学数据 A2CPS联合体的参与者，并发现新的代谢组和/或脂体学特征 与从急性疼痛转变为慢性疼痛有关。我们使用高分辨率HILIC-MS/MS和高分辨率 用于代谢物表征的解析GC-MS和荷电表面混合液色谱- 正、负电喷雾模式下的高分辨率、准确的质谱联用来表征血脂。 ODGC是维克森林大学学院精密医学中心之间的合作 加州大学戴维斯分校西海岸代谢组学中心。 由于患者招募工作出现意外延误，因此有必要提出行政补充要求 和在两个临床站点MCC1和MCC2的登记，以及由此导致的样本分析的延迟 ODGC。根据MCC的估计，预计代谢组学和脂类组学的所有样本 分析(共8400个样本)将于2025年8月底前收集，分析、数据和样本转移 将于2026年5月底前由ODGC完成。所要求的补充材料将确保成功 对全部样本进行分析，对预选的二级样本进行表征和量化 生物标记物，以及所产生的生物标记物数据与为 财团。